Morrison Foerster advised Bain Capital, an international investment company, on its acquisition of Mitsubishi Tanabe Pharma Corporation ("Mitsubishi Tanabe Pharma") in a carve-out transaction from Mitsubishi Chemical Group Co. for approximately 510 billion JPY (3.3 billion USD). This investment is led by Bain Capital's private equity and life sciences teams in Asia and North America.
Mitsubishi Tanabe Pharma was founded in 1678 and is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. Through the discovery and development of innovative pharmaceuticals to meet unmet medical needs, they develop solutions for immune-inflammation, vaccinations, central nervous system (CNS) diseases, diabetes, metabolic diseases, and other priority diseases.
The MoFo deal team advising Bain Capital was co-led by Tokyo M&A/Private Equity partners Jeremy White and Randy Laxer, M&A of counsel Takaki Sato and associates Bryce Gray, Ganesh Vaheisvaran, Ning Ning, Yusaku Narita, Agnes Hannah Petrucione, and Kasumi Matsukura.
